The estimated Net Worth of Brian M. Jr. Gallagher is at least $6.29 Millón dollars as of 2 July 2018. Brian Gallagher owns over 269,230 units of Telesis Bio Inc stock worth over $6,286,450 and over the last 7 years Brian sold TBIO stock worth over $0.
Brian has made over 2 trades of the Telesis Bio Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently Brian bought 269,230 units of TBIO stock worth $3,499,990 on 2 July 2018.
The largest trade Brian's ever made was buying 273,333 units of Telesis Bio Inc stock on 5 July 2017 worth over $4,099,995. On average, Brian trades about 180,854 units every 121 days since 2017. As of 2 July 2018 Brian still owns at least 3,697,912 units of Telesis Bio Inc stock.
You can see the complete history of Brian Gallagher stock trades at the bottom of the page.
Brian's mailing address filed with the SEC is C/O S.R. ONE, LIMITED, 161 WASHINGTON STREET, SUITE 500, CONSHOHOCKEN, PA, 19428.
Over the last 6 years, insiders at Telesis Bio Inc have traded over $269,224,467 worth of Telesis Bio Inc stock and bought 73,047,057 units worth $2,753,701,666 . The most active insiders traders include Sanofi, Plc Gsk y Human Genetic Therapies, In.... On average, Telesis Bio Inc executives and independent directors trade stock every 88 days with the average trade being worth of $7,100,681. The most recent stock trade was executed by Todd Robert Nelson on 4 May 2023, trading 2,575 units of TBIO stock currently worth $7,287.
sgi-dna, a wholly owned subsidiary of synthetic genomics inc., provides genomic solutions to advance scientific discovery. sgi-dna’s ever expanding suite of products, services, reagents, bioinformatics tools and instrumentation enables scientists to discover, design and build novel solutions for basic research, as well as for biomedical and industrial applications. sgi-dna’s genomic services include whole genome sequencing, dna synthesis, library design, bioinformatics, cell engineering, and plasmid dna cloning and purification. sgi-dna’s reagents include a complete suite of gibson assembly® and site directed mutagenesis kits as well as optimized cell lines such as vmax™ a novel, fast growing host system for molecular biology. to further enable synthetic biology workflows, sgi-dna offers the bioxp™ 3200 system. this fully automated genomics workstation allows the creation of double stranded dna fragments, automated cloning, as well as next generation sequencing dna library preparation.
Telesis Bio Inc executives and other stock owners filed with the SEC include: